$CLRB CEO James Caruso comments on reported case study results highlighting that a single administration of iopofosine I 131 produced a durable complete response lasting more than eight years in a heavily pretreated patient w/ aggressive, relapsed DLBCL. bit.ly/4i99BD1

Jarrod Longcor, COO of $CLRB, comments on the Company's recently reported DLBCL case study results, highlighting the broader potential of iopofosine I 131 across B-cell malignancies. bit.ly/4i99BD1

$CLRB reported case study results highlighting a durable complete response lasting more than eight years following a single administration of iopofosine I 131 in a heavily pretreated patient with aggressive, relapsed diffuse large B-cell lymphoma. bit.ly/4i99BD1

Jarrod Longcor, Cellectar COO, comments on efficacy data from Phase 2b CLOVER WaM subset analysis of iopofosine I 131 in patients R/R to BTK inhibitor therapy, presented today at #IWWM13: bit.ly/47X39ZK $CLRB

$CLRB announced Ph. 2b CLOVER WaM subgroup efficacy results presented at #IWWM13. The subgroup analysis of patients who received BTKi treatment immediately prior to iopofosine I 131 achieved 87.5% ORR, 79.2% MRR and 100% CBR with median DOR of 16 months. bit.ly/47X39ZK

Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225 bit.ly/4ftGAy4 $CLRB

Cellectar Biosciences and @SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer bit.ly/3Z1hBfJ

Today, around the U.S., we pause to honor the service and sacrifice of our veterans. At Cellectar Biosciences, we are grateful for those who have bravely served our country and are proud to support our nation's heroes.💙❤️ #VeteransDay #SupportOurVeterans #Community $CLRB

Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024 bit.ly/3O42gow #ConferenceCall #Cellectar $CLRB

Do you or someone you love have #HighGradeGlioma? Please consider our #PediatricClinicalTrial: pediatrichggtrial.com. Check out @TeamJack for more information about childhood brain cancer. #endbraintumors #CancelChildhoodCancer #pediatricbraintumor #curethekids $CLRB

If your child has been diagnosed with High-Grade Glioma, ask your doctor about our clinical trial for #HGG at pediatrichggtrial.com. Thank you to @PCRF_Kids for this very informative infographic. #PediatricBrainCancer #defeatDIPG #ChildhoodCancer $CLRB

🧬 Amazing talks and insights on Waldenstrom's at the IWWM Conference this week. Every step in research brings us closer advances for patient care! #IWWM2024 #CancerResearch #Prague #WMResearch #WaldenstromsMacroglobulinemia #Lymphoma $CLRB

Excited to have attended #IWWM2024 in Prague! Experts from around the world shared new research on Waldenstrom’s Macroglobulinemia, a rare type of lymphoma. Progress is being made, and we’re proud to be a Gold Sponsor for this event! #WMResearch #CancerCare #RareDiseases $CLRB

We are energized to attend the 2024 ASTRO Annual Meeting in Washington DC. Learn more about Cellectar Biosciences and our PDC Platform at booth 2145! #WeWhoCurie #RadOnc $CLRB

Our commitment to the Radiation Oncology community is rooted in collaboration and partnership. Cellectar is proud to be a gold sponsor for the #ASTRO2024 Annual Meeting. Learn more about our PDC platform at cellectar.com/moa. $CLRB @ASTRO_org #GoldSponsorship

Cellectar Biosciences is committed to solving challenges in pediatric cancer – learn about our #HighGradeGlioma trial now enrolling #PediatricCancerAwarenessMonth pediatrichggtrial.com/ #HGG #DIPG #braincancer #Childrenscancer #pediatriccancer #PediatricBrainCancer $CLRB

Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom’s Macroglobulinemia bit.ly/3AHVJMU #IWWM12 #Waldenstroms #Presentations #Oncology #ClinicalResearch #BloodCancer $CLRB

James Caruso of Cellectar Biosciences discusses the company's breakthrough PDC technology and upcoming pivotal data, in this interview with @SeekingAlpha . Big things ahead! bit.ly/46BQhqq #Pharma #HealthcareInnovation $CLRB

Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update bit.ly/3WDAFhI #biopharma #radiopharmaceuticals #iopofosine #conferencecall #corporateupdate $CLRB